BRAF and melanoma: Most advance and successful examples include targeting BCR-ABL with imatinib in chronic myeloid leukemia, inhibiting EGFR with cetuximab in colorectal cancer, antagonizing BRAF with vemurafenib in melanoma, and inhibiting multiple tyrosine kinases with lenvatinib in hepatocellular carcinoma (Cunningham et al., 2004; Baccarani et al., 2009; Shaitelman et al., 2015; Kudo et al., 2018).